Article
Immunology
Beatriz G. Perez-Nievas, Louisa Johnson, Paula Beltran-Lobo, Martina M. Hughes, Luciana Gammallieri, Francesca Tarsitano, Monika A. Myszczynska, Irina Vazquez-Villasenor, Maria Jimenez-Sanchez, Claire Troakes, Stephen B. Wharton, Laura Ferraiuolo, Wendy Noble
Summary: The pathological interactions between beta-amyloid (A beta) and tau contribute to synapse loss and cognitive decline in Alzheimer's disease (AD). Reactive astrocytes play a prominent role in AD brain and exacerbate the synaptotoxic effects of A beta through the interaction of astrocytic CXCL1 and neuronal CXCR2 receptors, suggesting a potential novel therapeutic target.
JOURNAL OF NEUROINFLAMMATION
(2021)
Review
Neurosciences
Guimei Zhang, Zicheng Wang, Huiling Hu, Meng Zhao, Li Sun
Summary: Alzheimer's disease is a common type of age-related dementia, where dysregulated microglia activity can lead to chronic neuroinflammation, promote pathological protein accumulation, and impair mitophagy. Targeting microglia may offer new therapeutic interventions for the disease.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2021)
Review
Biochemistry & Molecular Biology
Moazzama Akbar, Anam Shabbir, Kanwal Rehman, Muhammad Sajid Hamid Akash, Muhammad Ajmal Shah
Summary: Berberine, an important quinoline alkaloid, shows potential as a promising substance for treating Alzheimer's disease (AD) by offering neuroprotective effects and reducing the deposition of amyloid plaques and neurofibrillary tangles. It also exhibits a protective effect against risk factors associated with AD, such as neuroinflammation and oxidative stress. Further research is needed to explore the bioavailability, safety, and new perspectives of berberine in limiting AD-related pathogenesis and risk factors.
JOURNAL OF FOOD BIOCHEMISTRY
(2021)
Review
Geriatrics & Gerontology
Yuehua Huang, Xiaoyu Li, Guifei Luo, Junli Wang, Ranhui Li, Chuyi Zhou, Teng Wan, Fenglian Yang
Summary: This paper reviews the recent research progress on pyroptosis and focuses on the pathogenic roles of pyroptosis in Alzheimer's disease (AD) and the potential of targeted inhibition of inflammasome-dependent pyroptosis for AD treatment.
FRONTIERS IN AGING NEUROSCIENCE
(2022)
Review
Pharmacology & Pharmacy
Benjamin R. Troutwine, Laylan Hamid, Colton R. Lysaker, Taylor A. Strope, Heather M. Wilkins
Summary: Genetic variation in the APOE gene is associated with the risk of Alzheimer's disease. The APOE epsilon 4 alleles are the strongest genetic risk factor for late onset sporadic AD, while the APOE epsilon 2 alleles have lower risk and the APOE epsilon 3 alleles have neutral risk.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Neurosciences
Kelly Ceyzeriat, Benjamin B. Tournier, Philippe Millet, Giovanna Dipasquale, Nikolaos Koutsouvelis, Giovanni B. Frisoni, Valentina Garibotto, Thomas Zilli
Summary: This study found that low-dose radiation therapy (LD-RT) reduced amyloid load and possibly neuroinflammation markers in early-stage Alzheimer's disease, but did not impact tauopathy.
JOURNAL OF ALZHEIMERS DISEASE
(2022)
Review
Medicine, Research & Experimental
William J. Ray, Virginie Buggia-Prevot
Summary: Genetic studies have shown the central role of beta-amyloid in autosomal dominant AD, but amyloid-targeted therapies have not been successful in slowing disease progression. Microglia may play a role in promoting tau pathology after amyloid deposition, leading to neurodegeneration.
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021
(2021)
Article
Plant Sciences
Caixia Zang, Hui Liu, Junmei Shang, Hanyu Yang, Lu Wang, Chanjuan Sheng, Zihong Zhang, Xiuqi Bao, Yang Yu, Xinsheng Yao, Dan Zhang
Summary: The study demonstrates that GJ-4 improves cognitive deficits in APP/PS1 transgenic mice by reducing A beta levels, inhibiting tau protein phosphorylation, and suppressing neuroinflammatory responses. These findings provide a basis for further development of GJ-4 as a potential treatment for AD.
Article
Immunology
Xiao-ying Sun, Ling-jie Li, Quan-Xiu Dong, Jie Zhu, Ya-ru Huang, Sheng-jie Hou, Xiao-lin Yu, Rui-tian Liu
Summary: The study demonstrated that rutin could inhibit tau aggregation and tau oligomer-induced cytotoxicity, reduce the production of proinflammatory cytokines, protect neuronal morphology from toxic tau oligomers, and promote microglial uptake of extracellular tau oligomers. In a Tau-P301S mouse model, rutin also reduced pathological tau levels, regulated tau hyperphosphorylation, suppressed gliosis and neuroinflammation, prevented microglial synapse engulfment, and rescued synapse loss, resulting in a significant improvement of cognition. These findings suggest that rutin is a promising drug candidate for Alzheimer's disease treatment by targeting both tau and amyloid beta pathology.
JOURNAL OF NEUROINFLAMMATION
(2021)
Article
Geriatrics & Gerontology
Jiacheng Chen, Ning Guo, Yuting Ruan, Yingren Mai, Wang Liao, Yanqing Feng
Summary: This study found that isoniazid administration can effectively improve cognitive performance, clear Aβ plaques, protect dendritic synapses, and reduce innate immune cells around the Aβ plaques in a transgenic mouse model of Alzheimer's disease. These results suggest that isoniazid could be a potential drug for AD treatment.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Review
Biochemistry & Molecular Biology
Ziyad M. Althafar
Summary: This study summarizes the molecular pathogenesis of Alzheimer's disease (AD), the activities of microglia in the adult brain, the role of microglia in the aging brain, and the significance of targeting microglia for the treatment of AD.
Article
Neurosciences
Qingze Zeng, Kaicheng Li, Xiao Luo, Shuyue Wang, Xiaopei Xu, Yeerfan Jiaerken, Xiaocao Liu, Luwei Hong, Hui Hong, Zheyu Li, Yanv Fu, Tianyi Zhang, Yanxing Chen, Zhirong Liu, Peiyu Huang, Minming Zhang, Alzheimer's Disease Neuroimaging Initiative (ADNI) Behalf Alzheimers Dis Neuroimaging Initiat ADNI
Summary: This study confirms the relationship between glymphatic dysfunction and pathologic changes in Alzheimer's disease. The results show that impaired glymphatic dysfunction contributes to the accumulation of pathological tau protein, and this association is mediated by the microglia inflammatory process. These findings may provide evidence for the development of novel treatment strategies targeting neuroinflammation in the early stages of the disease.
NEUROBIOLOGY OF DISEASE
(2022)
Article
Geriatrics & Gerontology
Qing-Qing Tao, Rong-Rong Lin, Yi-He Chen, Zhi-Ying Wu
Summary: Alzheimer's disease is the most common neurodegenerative disease characterized by the accumulation of Aβ and tau in the brain. The dysfunction of the blood brain barrier (BBB) is increasingly recognized as a causative factor of cognitive impairment, but its role in the pathogenesis of AD is still not fully understood. Additional research is needed to determine the underlying mechanisms between BBB dysfunction and AD, as well as explore new therapies for BBB regulation to treat AD in the future.
Article
Biochemistry & Molecular Biology
Kirsty Hamilton, Kate Morrow, Ermione Markantoni, Jenni Harvey
Summary: The accumulation of amyloid-beta (A beta) and hyper-phosphorylated tau in the brain is associated with hippocampal synaptic dysfunction and cognitive deficits in Alzheimer's disease (AD). Recent research has found that A beta can lead to mis-localisation of tau in synapses, resulting in impaired synaptic function. However, leptin, a hormone involved in regulating appetite, has been shown to protect against A beta-induced toxicity in AD models. This study demonstrates that leptin can also prevent tau-related synaptic dysfunction, providing further evidence for the neuroprotective properties of leptin in the early stages of AD.
JOURNAL OF NEUROCHEMISTRY
(2023)
Review
Behavioral Sciences
RuoLan Cai, YangYang Wang, ZhenTing Huang, Qian Zou, YinShuang Pu, Changyin Yu, Zhiyou Cai
Summary: ROCK activation can promote the occurrence of Alzheimer's disease and may involve a positive feedback loop between Aβ and ROCK. Additionally, ROCK can also promote the formation of neurofibrillary tangles and exacerbate neuroinflammatory responses.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Article
Integrative & Complementary Medicine
Yan Liu, Xin-Juan Wang, Na Wang, Cai-Lian Cui, Liu-Zhen Wu
AMERICAN JOURNAL OF CHINESE MEDICINE
(2016)
Article
Neurosciences
Na Wang, Feifei Ge, Cailian Cui, Yijing Li, Xiaowei Sun, Linlin Sun, Xinjuan Wang, Shuli Liu, Haolin Zhang, Yan Liu, Meng Jia, Mingda Yang
NEUROPSYCHOPHARMACOLOGY
(2018)
Article
Neurosciences
Feifei Ge, Na Wang, Cailian Cui, Yijing Li, Yan Liu, Yaoying Ma, Shuli Liu, Haolin Zhang, Xiaowei Sun
NEUROPSYCHOPHARMACOLOGY
(2017)
Article
Toxicology
Ran You, Yuen-Shan Ho, Clara Hiu-Ling Hung, Yan Liu, Chun-Xia Huang, Hei-Nga Chan, See-Lok Ho, Sheung-Yeung Lui, Hung-Wing Li, Raymond Chuen-Chung Chang
PARTICLE AND FIBRE TOXICOLOGY
(2018)
Article
Neurosciences
Chunxia Huang, John Man-Tak Chu, Yan Liu, Raymond Chuen-Chung Chang, Gordon Tin-Chun Wong
Review
Medicine, Research & Experimental
Yan Liu, Tim Yan, John Man-Tak Chu, Ying Chen, Sophie Dunnett, Yuen-Shan Ho, Gordon Tin-Chun Wong, Raymond Chuen-Chung Chang
LABORATORY INVESTIGATION
(2019)
Article
Multidisciplinary Sciences
Ran You, Yan Liu, Raymond Chuen-Chung Chang
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
(2019)
Article
Biochemistry & Molecular Biology
Chunxia Huang, John Man Tak Chu, Yan Liu, Vivian Suk Wai Kwong, Raymond Chuen Chung Chang, Gordon Tin Chun Wong
Summary: This study investigated the effects of sevoflurane on a specific mouse model with pre-existing Alzheimer's disease neuropathology. The results showed that sevoflurane led to cognitive deterioration and affected glutamate transporter, MAPK signaling, and neuronal apoptosis. However, no significant impact was observed in wild-type mice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Xinjuan Wang, Yan Liu, Meng Jia, Xiaowei Sun, Na Wang, Yijing Li, Cailian Cui